Harrington Discovery Institute at University Hospitals
Peter Bernstein is a prominent figure in the fields of organic chemistry and drug discovery, currently serving as a Member of the Scientific Advisory Board at Neurosterix, Nxera, Richter Gedeon Nyrt., and previously at Addex Therapeutics. With extensive experience as a Principal/Owner at PhaRmaB LLC, Bernstein consults on small molecule drug discovery and development. In academia, Bernstein holds positions as an Adjunct Professor at both the University of Delaware and Drexel University College of Medicine, where contributions include leading a COBRE grant and advising on biochemistry and molecular biology. Additionally, Bernstein is a Strategic Advisor at the Harrington Discovery Institute, mentoring scientists through early discovery phases, and has played a significant editorial role in various scientific publications since 2006. Education includes a PhD in Organic Chemistry from Columbia University and postdoctoral training at the University of Wisconsin-Madison.
This person is not in any teams
Harrington Discovery Institute at University Hospitals
The Harrington Discovery Institute at University Hospitals in Cleveland, OH – part of The Harrington Project for Discovery & Development – aims to advance medicine and society by enabling our nation’s most inventive scientists to turn their discoveries into medicines that improve human health. Harrington Discovery Institute was created in 2012 with a $50 million founding gift from the Harrington family and instantiates the commitment they share with University Hospitals to a Vision for a ‘Better World’.